More trials for Insmed’s Arikayce

Insmed Inc. (Nasdaq: INSM) will conduct two Phase 3 studies of its inhaled antibiotic Arikayce which disappointed investors who had hoped for regulatory approval without additional clinical trials. Shares of the biopharmaceutical plummeted $4.28 to close at $12.97.